...
首页> 外文期刊>European journal of gastroenterology and hepatology >Effect of two different doses of metronidazole and tetracycline in bismuth triple therapy on eradication of Helicobacter pylori and its resistant strains.
【24h】

Effect of two different doses of metronidazole and tetracycline in bismuth triple therapy on eradication of Helicobacter pylori and its resistant strains.

机译:铋三联疗法中两种不同剂量的甲硝唑和四环素对根除幽门螺杆菌及其耐药菌株的影响。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Classic triple therapy with bismuth, tetracycline and metronidazole is one of the most economic and effective regimens for the eradication of Helicobacter pylori. The aim of the study was to assess the efficacy of two different doses of tetracycline (TET) and metronidazole (MET) on cure of H. pylori infection and its MET-resistant strains. MATERIAL AND METHODS: A total of 131 patients with duodenal ulcer were randomized into three groups and received the following medication for 2 weeks: group A, colloidal bismuth subcitrate (CBS) 3 x 120 mg + TET 3 x 500 mg + MET 3 x 250 mg/day; group B, CBS 3 x 120 mg + TET 3 x 500 mg + MET 3 x 125 mg/day; group C, CBS 3 x 120 mg + TET 3 x 250 mg + MET 3 x 125 mg/day. Control endoscopy was performed after 6 weeks. Two biopsy specimens from antral and three from corpus mucosa were taken for a urease test, histology and culture. Eradication was concluded if all three tests were negative for H. pylori. MET resistance was determined by the disc diffusion method. RESULTS: In total, 121 patients completed the study. Only two of the 43 patients in group A discontinued the therapy due to intolerance. Cure of H. pylori infection was achieved by per protocol analysis in 33 of 43 patients in group A (76.7%), in 20 of 40 patients in group B (50%) and in 20 of 38 patients in group C (52.6%) (P < 0.05 for A versus B or C). Forty-two out of 112 patients had H. pylori strains resistant to MET (42%). In each group, the cure rate of infection was higher in patients with MET-sensitive H. pylori than in MET-resistant H. pylori (80.7% versus 64.2% in group A, 60% versus 38.8% in group B and 52.6% versus 40% in group C, respectively). Increase of MET dose from 375 mg (in groups B and C) to 750 mg/day (in group A) seems to augment the eradication of MET-sensitive as well as MET-resistant strains (up from 52% to 84% and from 39% to 64%, respectively; P < 0.05). CONCLUSION: Cure rate of H. pylori infection under classic triple therapy remains unaffected by dose reduction of tetracycline but not of metronidazole. In countries with a high prevalence of metronidazole resistance, such as Iran, higher doses of metronidazole are probably needed to increase the cure rate of bismuth triple therapy.
机译:背景:铋,四环素和甲硝唑的经典三联疗法是根除幽门螺杆菌最经济,最有效的方案之一。该研究的目的是评估两种不同剂量的四环素(TET)和甲硝唑(MET)对幽门螺杆菌感染及其MET耐药菌株的疗效。材料与方法:将131例十二指肠溃疡患者随机分为三组,并接受以下为期2周的药物治疗:A组,次柠檬酸铋胶体(CBS)3 x 120 mg + TET 3 x 500 mg + MET 3 x 250毫克/天B组,CBS 3 x 120毫克+ TET 3 x 500毫克+ MET 3 x 125毫克/天; C组,CBS 3 x 120毫克+ TET 3 x 250毫克+ MET 3 x 125毫克/天。 6周后进行对照内窥镜检查。取了两个来自肛门的活组织检查标本和三个来自corp体粘膜的活检标本进行尿素酶测试,组织学和培养。如果所有三个测试均对幽门螺杆菌阴性,则表明已根除。 MET抗性通过盘扩散法确定。结果:总共121例患者完成了研究。 A组43例患者中只有2例由于不耐受而终止治疗。通过方案分析,A组43例患者中的33例(76.7%),B组40例中的20例(50%)和C组38例中的20例(52.6%)实现了幽门螺杆菌感染的治愈(A对B或C的P <0.05)。 112例患者中有42例对MET耐药的幽门螺杆菌菌株(42%)。在每组中,MET敏感的幽门螺杆菌患者的感染治愈率均高于MET耐药的幽门螺杆菌(A组为80.7%对64.2%,B组为60%对38.8%,B组为52.6%对C组分别为40%)。将MET剂量从375 mg(B和C组)增加到750 mg /天(A组)似乎可以进一步根除MET敏感菌株和MET耐药菌株(从52%增加到84%分别为39%至64%; P <0.05)。结论:经典三联疗法对幽门螺杆菌感染的治愈率仍不受四环素剂量降低的影响,但不受甲硝唑的影响。在甲硝唑耐药性较高的国家(例如伊朗),可能需要更高剂量的甲硝唑才能提高铋三联疗法的治愈率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号